<DOC>
	<DOCNO>NCT02625935</DOCNO>
	<brief_summary>This multicenter , prospectively design study examine whether Prosigna score influence physician patient adjuvant treatment selection currently use prognostic factor . This study also examine impact test result patient ' report outcome , include decisional conflict status anxiety level .</brief_summary>
	<brief_title>Prospective Observational Study Evaluating Treatment Decision Impact ProsignaÂ® Early Stage Breast Cancer Patients</brief_title>
	<detailed_description>The primary objective study assess extent Prosigna test result affect medical oncologist 's treatment recommendation regard adjuvant chemotherapy actual treatment receive patient early stage breast cancer conventionally consider candidate genomic test base current treatment guideline . The oncologist 's initial recommendation base utilization tool algorithms base clinical pathologic factor . No genomic tool use initial assessment . Changes recommendation availability Prosigna test result include ( 1 ) hormonal therapy alone ( 2 ) hormonal therapy plus chemotherapy , ( 3 ) change type chemotherapy chemotherapy recommend test .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Surgically resect nodenegative , estrogen receptorpositive , HER2negative earlystage invasive breast cancer ( T1T2 , N0 , pN0 ( i+ ) , pN0 ( mol+ ) , M0 ) 1 . Estrogen receptor status evaluate Immunohistochemistry ( IHC ) 1 % stained tumor cell consider positive . 2 . HER2 status evaluate IHC and/or insitu fluorescence hybridization ( 0 1+ , 2+ consider negative absence insitu fluorescence hybridization ) . Postmenopausal female , define : 1 . Natural Amenorrhea &gt; 12 month , regardless age 2 . Bilateral oophorectomy , regardless age ( oophorectomy must carry least 4 week enter study ) 3 . Radiological castration amenorrhea &gt; 3 month , regardless age 4 . Hysterectomy postmenopausal blood level FSH/LH Able give inform consent Eligible treatment breast cancer adjuvant chemotherapy , determine treat physician ECOG performance status 0 1 Tumor specimen core needle biopsy ( CNB ) Tumor stage T3T4 Noninvasive breast cancer ( e.g. , Paget 's disease , DCIS ) Tumors node N0 , pN0 ( i+ ) , pN0 ( mol+ ) Tumors estrogen receptor ( ER ) negative HER2positive Have metastatic disease Have receive another genomic test prognosis early breast cancer ( i.e. , Oncotype Dx , Mammaprint , BCI ) Unable give inform consent Unable complete patient report outcome survey Have contraindication adjuvant chemotherapy , determine treat physician Age , performance status , significant comorbidities , etc . ECOG performance status &gt; 1</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prosigna</keyword>
	<keyword>estrogen receptor positive</keyword>
	<keyword>node negative</keyword>
	<keyword>HER2 negative</keyword>
</DOC>